Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Preclinical Characterization of Antioxidant Quinolyl Nitrone QN23 as a New Candidate for the Treatment of Ischemic Stroke

  • Martínez-Alonso, Emma
  • Escobar-Peso, Alejandro
  • Aliena-Valero, Alicia
  • Torregrosa, Germán
  • Chioua, Mourad
  • Fernández-Serra, Rocío
  • González-Nieto, Daniel
  • Ouahid, Youness
  • Salom, Juan B.
  • Masjuán, Jaime
  • Marco-Contelles, José
  • Alcázar, Alberto
Nitrones are encouraging drug candidates for the treatment of oxidative stress-driven diseases such as acute ischemic stroke (AIS). In a previous study, we found a promising quinolylnitrone, QN23, which exerted a neuroprotective effect in neuronal cell cultures subjected to oxygen–glucose deprivation and in experimental models of cerebral ischemia. In this paper, we update the biological and pharmacological characterization of QN23. We describe the suitability of intravenous administration of QN23 to induce neuroprotection in transitory four-vessel occlusion (4VO) and middle cerebral artery occlusion (tMCAO) experimental models of brain ischemia by assessing neuronal death, apoptosis induction, and infarct area, as well as neurofunctional outcomes. QN23 significantly decreased the neuronal death and apoptosis induced by the ischemic episode in a dose-dependent manner and showed a therapeutic effect when administered up to 3 h after post-ischemic reperfusion onset, effects that remained 11 weeks after the ischemic episode. In addition, QN23 significantly reduced infarct volume, thus recovering the motor function in a tMCAO model. Remarkably, we assessed the antioxidant activity of QN23 in vivo using dihydroethidium as a molecular probe for radical species. Finally, we describe QN23 pharmacokinetic parameters. All these results pointing to QN23 as an interesting and promising preclinical candidate for the treatment of AIS., This work was supported by the Instituto de Salud Carlos III and co-financed by the European Development Regional Fund (FEDER) through grants PI18/00255, RD16/0019/0006, and RD21/0006/0019 to J.M. and A.A., and RD16/0019/0008 and RD21/0006/0014 to J.B.S.; the MINECO grant SAF2015-65586-R to J.M.-C.; and the Comunidad de Madrid Neurocentro project B2017/BMD-3760 to D.G.-N.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Cerebroprotective Effects of the TLR4-Binding DNA Aptamer ApTOLL in a Rat Model of Ischemic Stroke and Thrombectomy Recanalization

  • Aliena-Valero, Alicia
  • Hernández Jiménez, Macarena
  • López Morales, Mikahela
  • Tamayo-Torres, Eva
  • Castelló-Ruiz, Maria
  • Piñeiro, David
  • Ribo, Marc
Aptamers; Cerebroprotection; Ischemic stroke, Aptàmers; Cerebroprotecció; Ictus isquèmic, Aptámeros; Cerebroprotección; Ictus isquémico, ApTOLL, a TLR4 modulator aptamer, has demonstrated cerebroprotective effects in a permanent ischemic stroke mouse model, as well as safety and efficacy in early phase clinical trials. We carried out reverse translation research according to STAIR recommendations to further characterize the effects and mechanisms of ApTOLL after transient ischemic stroke in rats and to better inform the design of pivotal clinical trials. Adult male rats subjected to transient middle cerebral artery occlusion were treated either with ApTOLL or the vehicle intravenously at different doses and time-points. ApTOLL was compared with TAK-242 (a TLR4 inhibitor). Female rats were also studied. After neurofunctional evaluation, brains were removed for infarct/edema volume, hemorrhagic transformation, and histologic determinations. Peripheral leukocyte populations were assessed via flow cytometry. ApTOLL showed U-shaped dose-dependent cerebroprotective effects. The maximum effective dose (0.45 mg/kg) was cerebroprotective when given both before reperfusion and up to 12 h after reperfusion and reduced the hemorrhagic risk. Similar effects occurred in female rats. Both research and clinical ApTOLL batches induced slightly superior cerebroprotection when compared with TAK-242. Finally, ApTOLL modulated circulating leukocyte levels, reached the brain ischemic tissue to bind resident and infiltrated cell types, and reduced the neutrophil density. These results show the cerebroprotective effects of ApTOLL in ischemic stroke by reducing the infarct/edema volume, neurofunctional impairment, and hemorrhagic risk, as well as the peripheral and local immune response. They provide information about ApTOLL dose effects and its therapeutic time window and target population, as well as its mode of action, which should be considered in the design of pivotal clinical trials., This study was sponsored by AptaTargets S.L. (Madrid, Spain) and co-funded by grants from the Spanish Ministry of Science, Innovation and Universities (RTC-2019-006795-1), Centro para el Desarrollo Tecnológico Industrial (IDI-20210746), and Instituto de Salud Carlos III (co-financed by the European Development Regional Fund “A Way to Achieve Europe”) (RD16/0019/0008 and RD21/0006/0014). The funders were not involved in the study design; collection, analysis, or interpretation of data; the writing of this article; or the decision to submit it for publication.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Identifying new blood biomarkers of neuroplasticity associated with rehabilitation outcomes after stroke

  • García Rodríguez, Nicolás
  • García-Gabilondo, Miguel
  • Rodriguez, Susana
  • Tejada Ezquerro, Pedro Ignacio
  • Miranda-Artieda, Zuberoa Maite
  • Ridao, Natalia
  • Buxo Masip, Xavier
  • Perez-Mesquida, Maria Engracia
  • Valor-Blanquer, Júlia
  • Penalba Morenilla, Anna
  • Pérez, Laura Mónica
  • Inzitari, Marco
  • Lamana Vallverdú, Marcel
  • Delgado Martínez, María Pilar
  • Rosell Novel, Anna
Biomarker; Neuroplasticity; Recovery, Biomarcador; Neuroplasticitat; Recuperació, Biomarcador; Neuroplasticidad; Recuperación, Blood biomarkers in stroke patients seek to guide decision-making in clinical practice, but research on those that respond to brain recovery and their relationship with rehabilitation is still limited. Our aim was to explore the value of known neuroplasticity-related molecules, such as endostatin, growth and differentiation factor-10 (GDF-10), urokinase-type plasminogen activator (uPA) and the uPA receptor (uPAR), as blood biomarkers of recovery during poststroke rehabilitation. In an observational, prospective and multicenter study, biomarker levels were assessed after stroke in a cohort of 62 stroke patients with outcome evaluations and blood sampling before starting rehabilitation and during therapy at 1, 3 and 6 months of first visit, and in 43 control subjects. Serum levels were determined by Enzyme-Linked Immunosorbent Assay (ELISA) together with a complete battery of sensorimotor and functional tests/scales: modified Rankin Scale (mRS), Barthel Index (BI), Fugl-Meyer Assessment (FMA) for the upper extremity, Functional Ambulation Categories (FAC), Chedoke Arm and Hand Activity Inventory (CAHAI), 10-m walk test and the Medical Research Council (MRC). Statistical mixed linear models were built to investigate its prognostic value. The results revealed that, compared to controls, only endostatin was significantly increased at baseline after stroke (p < 0.01). Interestingly, the highest baseline GDF-10 or uPAR values were related to unfavorable scores during the complete follow-up (p < 0.05 for walking speed or MRC with GDF-10, and for FMA or MRC with uPAR), whereas decreased endostatin or increased GDF-10 biomarker changes at first month of rehabilitation were related to greater sensorimotor and functional improvements during follow-up (p < 0.05 for FMA or MRC with endostatin, and CAHAI or BI with GDF-10). Our results position endostatin, GDF-10 and uPAR as potential blood biomarkers to monitor recovery during rehabilitation after stroke., N.G-R. is doing a doctorate at the Departament de Medicina de la Universitat Autònoma de Barcelona. Research grants from the Instituto de Salud Carlos III with European Regional Development or Next Generation Founds to A.R. or J.B.S. supported this study (PI16/00981, PI19/00186, RD16/0019/0021, RD16/0019/0008, RD21/0006/0007, and RD21/0006/0014), as well as the 2021-SGR-0656 programme from the Generalitat de Catalunya-AGAUR. N.G-R. received a predoctoral fellowship from VHIR, and MG-G. received a research support grant (PERIS, SLT017/20/000197).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Comparative Proteomics Unveils LRRFIP1 as a New Player in the DAPK1 Interactome of Neurons Exposed to Oxygen and Glucose Deprivation

  • Gregorio-Rocasolano Barbany, Núria de|||0000-0001-5248-7525
  • Guirao, Verónica
  • Ponce, Jovita
  • Melià Sorolla, Marc|||0000-0002-4425-1077
  • Aliena-Valero, Alicia
  • García Serran, Alexia|||0000-0003-1630-1302
  • Salom, Juan B.|||0000-0002-4162-6101
  • Dávalos, Antoni|||0000-0003-2949-5679
  • Martí-Sistac, Octavi
  • Gasull Dalmau, Teresa|||0000-0002-9321-1741
Death-associated protein kinase 1 (DAPK1) is a pleiotropic hub of a number of networked distributed intracellular processes. Among them, DAPK1 is known to interact with the excitotoxicity driver NMDA receptor (NMDAR), and in sudden pathophysiological conditions of the brain, e.g., stroke, several lines of evidence link DAPK1 with the transduction of glutamate-induced events that determine neuronal fate. In turn, DAPK1 expression and activity are known to be affected by the redox status of the cell. To delineate specific and differential neuronal DAPK1 interactors in stroke-like conditions in vitro, we exposed primary cultures of rat cortical neurons to oxygen/glucose deprivation (OGD), a condition that increases reactive oxygen species (ROS) and lipid peroxides. OGD or control samples were co-immunoprecipitated separately, trypsin-digested, and proteins in the interactome identified by high-resolution LC-MS/MS. Data were processed and curated using bioinformatics tools. OGD increased total DAPK1 protein levels, cleavage into shorter isoforms, and dephosphorylation to render the active DAPK1 form. The DAPK1 interactome comprises some 600 proteins, mostly involving binding, catalytic and structural molecular functions. OGD up-regulated 190 and down-regulated 192 candidate DAPK1-interacting proteins. Some differentially up-regulated interactors related to NMDAR were validated by WB. In addition, a novel differential DAPK1 partner, LRRFIP1, was further confirmed by reverse Co-IP. Furthermore, LRRFIP1 levels were increased by pro-oxidant conditions such as ODG or the ferroptosis inducer erastin. The present study identifies novel partners of DAPK1, such as LRRFIP1, which are suitable as targets for neuroprotection.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Functional Recovery and Serum Angiogenin Changes According to Intensity of Rehabilitation Therapy After Stroke

  • García Rodríguez, Nicolás|||0000-0001-8839-0514
  • Rodriguez Gonzalez, Susana|||0000-0002-6170-5253
  • Tejada, Pedro Ignacio
  • Miranda-Artieda, Zuberoa Maite
  • Ridao, Natalia
  • Buxo Masip, Xavier|||0000-0001-6814-7373
  • Pérez-Mesquida, María Engracia|||0000-0001-7949-7678
  • Beseler, Maria Rosario
  • Salom, Juan B.|||0000-0002-4162-6101
  • Pérez, Laura Mónica|||0000-0003-3152-9882
  • Inzitari, Marco|||0000-0002-3796-0625
  • Otero-Villaverde, Sergio
  • Martin-Mourelle, Rosa
  • Molleda, Mercedes|||0000-0001-5393-9837
  • Quintana, Manuel|||0000-0003-0288-9088
  • Olivé-Gadea, Marta|||0000-0003-4637-1598
  • Penalba, Anna
  • Rosell Novel, Anna|||0000-0003-1082-3599
Rehabilitation is still the only treatment available to improve functional status after the acute phase of stroke. Most clinical guidelines highlight the need to design rehabilitation treatments considering starting time, intensity, and frequency, according to the tolerance of the patient. However, there are no homogeneous protocols and the biological effects are under investigation. To investigate the impact of rehabilitation intensity (hours) after stroke on functional improvement and serum angiogenin (ANG) in a 6-month follow-up study. A prospective, observational, longitudinal, and multicenter study with three cohorts: strokes in intensive rehabilitation therapy (IRT, minimum 15 h/week) vs. conventional therapy (NO-IRT, <15 h/week), and controls subjects (without known neurological, malignant, or inflammatory diseases). A total of seven centers participated, with functional evaluations and blood sampling during follow-up. The final cohort includes 62 strokes and 43 controls with demographic, clinical, blood samples, and exhaustive functional monitoring. The median (IQR) number of weekly hours of therapy was different: IRT 15 (15-16) vs. NO-IRT 7.5 (5-9), p < 0.01, with progressive and significant improvements in both groups. However, IRT patients showed earlier improvements (within 1 month) on several scales (CAHAI, FMA, and FAC; p < 0.001) and the earliest community ambulation achievements (0.89 m/s at 3 months). There was a significant difference in ANG temporal profile between the IRT and NO-IRT groups (p < 0.01). Additionally, ANG was elevated at 1 month only in the IRT group (p < 0.05) whereas it decreased in the NO-IRT group (p < 0.05). Our results suggest an association of rehabilitation intensity with early functional improvements, and connect the rehabilitation process with blood biomarkers.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Cerebroprotective Effects of the TLR4-Binding DNA Aptamer ApTOLL in a Rat Model of Ischemic Stroke and Thrombectomy Recanalization

  • Aliena-Valero, Alicia
  • Hernández Jiménez, Macarena
  • López Morales, Mikahela
  • Tamayo-Torres, Eva
  • Castelló-Ruiz, Maria
  • Piñeiro, David
  • Ribo, Marc
Aptamers; Cerebroprotection; Ischemic stroke, Aptàmers; Cerebroprotecció; Ictus isquèmic, Aptámeros; Cerebroprotección; Ictus isquémico, ApTOLL, a TLR4 modulator aptamer, has demonstrated cerebroprotective effects in a permanent ischemic stroke mouse model, as well as safety and efficacy in early phase clinical trials. We carried out reverse translation research according to STAIR recommendations to further characterize the effects and mechanisms of ApTOLL after transient ischemic stroke in rats and to better inform the design of pivotal clinical trials. Adult male rats subjected to transient middle cerebral artery occlusion were treated either with ApTOLL or the vehicle intravenously at different doses and time-points. ApTOLL was compared with TAK-242 (a TLR4 inhibitor). Female rats were also studied. After neurofunctional evaluation, brains were removed for infarct/edema volume, hemorrhagic transformation, and histologic determinations. Peripheral leukocyte populations were assessed via flow cytometry. ApTOLL showed U-shaped dose-dependent cerebroprotective effects. The maximum effective dose (0.45 mg/kg) was cerebroprotective when given both before reperfusion and up to 12 h after reperfusion and reduced the hemorrhagic risk. Similar effects occurred in female rats. Both research and clinical ApTOLL batches induced slightly superior cerebroprotection when compared with TAK-242. Finally, ApTOLL modulated circulating leukocyte levels, reached the brain ischemic tissue to bind resident and infiltrated cell types, and reduced the neutrophil density. These results show the cerebroprotective effects of ApTOLL in ischemic stroke by reducing the infarct/edema volume, neurofunctional impairment, and hemorrhagic risk, as well as the peripheral and local immune response. They provide information about ApTOLL dose effects and its therapeutic time window and target population, as well as its mode of action, which should be considered in the design of pivotal clinical trials., This study was sponsored by AptaTargets S.L. (Madrid, Spain) and co-funded by grants from the Spanish Ministry of Science, Innovation and Universities (RTC-2019-006795-1), Centro para el Desarrollo Tecnológico Industrial (IDI-20210746), and Instituto de Salud Carlos III (co-financed by the European Development Regional Fund “A Way to Achieve Europe”) (RD16/0019/0008 and RD21/0006/0014). The funders were not involved in the study design; collection, analysis, or interpretation of data; the writing of this article; or the decision to submit it for publication.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Identifying new blood biomarkers of neuroplasticity associated with rehabilitation outcomes after stroke

  • García Rodríguez, Nicolás
  • García-Gabilondo, Miguel
  • Rodriguez, Susana
  • Tejada Ezquerro, Pedro Ignacio
  • Miranda-Artieda, Zuberoa Maite
  • Ridao, Natalia
  • Buxo Masip, Xavier
  • Perez-Mesquida, Maria Engracia
  • Valor-Blanquer, Júlia
  • Penalba Morenilla, Anna
  • Pérez, Laura Mónica
  • Inzitari, Marco
  • Lamana Vallverdú, Marcel
  • Delgado Martínez, María Pilar
  • Rosell Novel, Anna
Biomarker; Neuroplasticity; Recovery, Biomarcador; Neuroplasticitat; Recuperació, Biomarcador; Neuroplasticidad; Recuperación, Blood biomarkers in stroke patients seek to guide decision-making in clinical practice, but research on those that respond to brain recovery and their relationship with rehabilitation is still limited. Our aim was to explore the value of known neuroplasticity-related molecules, such as endostatin, growth and differentiation factor-10 (GDF-10), urokinase-type plasminogen activator (uPA) and the uPA receptor (uPAR), as blood biomarkers of recovery during poststroke rehabilitation. In an observational, prospective and multicenter study, biomarker levels were assessed after stroke in a cohort of 62 stroke patients with outcome evaluations and blood sampling before starting rehabilitation and during therapy at 1, 3 and 6 months of first visit, and in 43 control subjects. Serum levels were determined by Enzyme-Linked Immunosorbent Assay (ELISA) together with a complete battery of sensorimotor and functional tests/scales: modified Rankin Scale (mRS), Barthel Index (BI), Fugl-Meyer Assessment (FMA) for the upper extremity, Functional Ambulation Categories (FAC), Chedoke Arm and Hand Activity Inventory (CAHAI), 10-m walk test and the Medical Research Council (MRC). Statistical mixed linear models were built to investigate its prognostic value. The results revealed that, compared to controls, only endostatin was significantly increased at baseline after stroke (p < 0.01). Interestingly, the highest baseline GDF-10 or uPAR values were related to unfavorable scores during the complete follow-up (p < 0.05 for walking speed or MRC with GDF-10, and for FMA or MRC with uPAR), whereas decreased endostatin or increased GDF-10 biomarker changes at first month of rehabilitation were related to greater sensorimotor and functional improvements during follow-up (p < 0.05 for FMA or MRC with endostatin, and CAHAI or BI with GDF-10). Our results position endostatin, GDF-10 and uPAR as potential blood biomarkers to monitor recovery during rehabilitation after stroke., N.G-R. is doing a doctorate at the Departament de Medicina de la Universitat Autònoma de Barcelona. Research grants from the Instituto de Salud Carlos III with European Regional Development or Next Generation Founds to A.R. or J.B.S. supported this study (PI16/00981, PI19/00186, RD16/0019/0021, RD16/0019/0008, RD21/0006/0007, and RD21/0006/0014), as well as the 2021-SGR-0656 programme from the Generalitat de Catalunya-AGAUR. N.G-R. received a predoctoral fellowship from VHIR, and MG-G. received a research support grant (PERIS, SLT017/20/000197).